Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO

Eisai CEO Haruo Naito An expanded collaboration with Biogen for its investigational anti-amyloid beta (Aβ) antibody aducanumab will provide Eisai with insights that could be leveraged for the development of other pipelines for Alzheimer’s disease, Haruo Naito, CEO of the...read more